Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

There are three treatment cohorts and the inclusion of patients in governed by the dose-limiting toxicities in the previous cohort. * the first three patients will receive a dose of 50 µg of Theravac® * second cohort of three patients will receive a dose of 150 µg Theravac® * the third cohort of three patients will receive a dose of 250 µg Theravac® and eventually a total of 14 patients will complete the step with the highest dose. All the patients will receive four immunizations every three weeks in two intradermal sites and in two subcutaneous sites.